A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Registration Number
NCT06194877
Lead Sponsor
MapKure, LLC
Brief Summary

The primary objectives of Part 1 of this study are to:
...

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
64
Inclusion Criteria
  1. Participants with histologically confirmed advanced or metastatic solid tumors who have had documented disease progression by RECIST criteria during or after at least 1 prior line of systemic anticancer therapies in the representative population or are unable to receive standard of care therapy(ies) as noted by local guidelines.
  2. Part 1 (Dose Finding): Participants with CRC with a known mutation status by local testing and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS in the archival tumor sample or fresh tumor biopsy.
  3. Part 2 (Dose Expansion): Participants must have a known mutation status by local testing and meet one of the following criteria according to the group they are enrolled into: Group 1: Participants with CRC that harbors KRAS or NRAS mutations in the archival tumor sample or fresh tumor biopsy. Group 2: Participants with PDAC that harbors KRAS mutations in the archival tumor sample or fresh tumor biopsy.
  4. Participants must provide archival tumor tissue or a fresh tumor biopsy for retrospective mutation status analysis.
  5. Participants must have radiologically measurable disease as defined per RECIST v1.1 at screening.
  6. Eastern Cooperative Oncology Group performance status of ≤1 at screening.
  7. Adequate hematologic and organ function, as indicated by defined laboratory values, prior to Cycle 1 Day 1.
  8. Adequate cardiac function.

Key

Read More
Exclusion Criteria
  1. Participants receiving cancer therapy (chemotherapy or other systemic anticancer therapies, immunotherapy, radiation therapy, or surgery) at the time of Cycle 1 Day 1.
  2. Active infection requiring systemic treatment at the start of the study treatment.
  3. Clinically significant cardiovascular disease and / or events within 6 months of signing the informed consent form.
  4. Participants with toxicities that have not recovered to Grade ≤1 or stabilized and those Grade 2 toxicities listed as permitted in other eligibility criteria.
  5. Participants with a history of pneumonitis or interstitial lung disease.
  6. Participants with immune-related toxicities that have not resolved with appropriate management.
  7. History or presence of gastrointestinal disease or other condition known to interfere with the absorption of drugs.
  8. History of ulcerative colitis or Crohn's disease or protracted and ongoing immune-mediated diarrhea from prior checkpoint inhibitor use.
  9. History of corneal perforation, keratitis, or severe dry eye.
  10. Current evidence of symptomatic central nervous system metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression.
  11. Any active malignancy ≤3 years before Cycle 1 Day 1 except for the specific cancer under investigation in this study and any localized or noninvasive cancer that has been treated curatively.
  12. Known hypersensitivity to rapidly accelerated fibrosarcoma (RAF) inhibitors, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or their excipients.
  13. Any known history of Grade ≥3 toxicity lasting >14 days from another RAF, mitogen activated protein kinase, extracellular signal-regulated kinase, or anti-EGFR antibody inhibitor requiring discontinuation of treatment from these drugs.
  14. Receiving any treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor or inducer ≤14 days (or 5 half-lives, whichever is longer) before Cycle 1 Day 1 and until completion of dosing with BGB-3245 for at least 5 half-lives.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply. Summary of key criteria provided.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part 1: Dose Finding PartBGB-3245Participants with advanced or metastatic CRC and with known mutation status and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS and with documented disease progression by RECIST during or after at least 1 line of prior therapy will be enrolled into 4 planned sequentially run cohorts. Participants will receive escalating doses of BGB-3245 in combination with panitumumab to establish the MTD and RP2D by assessing the safety, tolerability, preliminary antitumor activity, and pharmacokinetics (PK) for the combination of BGB-3245 with panitumumab.
Part 2: Dose Expansion Part, Group 1BGB-3245Participants with advanced or metastatic CRC that harbors KRAS or NRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
Part 2: Dose Expansion Part, Group 2BGB-3245Participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that harbors KRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
Part 1: Dose Finding PartPanitumumabParticipants with advanced or metastatic CRC and with known mutation status and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS and with documented disease progression by RECIST during or after at least 1 line of prior therapy will be enrolled into 4 planned sequentially run cohorts. Participants will receive escalating doses of BGB-3245 in combination with panitumumab to establish the MTD and RP2D by assessing the safety, tolerability, preliminary antitumor activity, and pharmacokinetics (PK) for the combination of BGB-3245 with panitumumab.
Part 2: Dose Expansion Part, Group 1PanitumumabParticipants with advanced or metastatic CRC that harbors KRAS or NRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
Part 2: Dose Expansion Part, Group 2PanitumumabParticipants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that harbors KRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
Primary Outcome Measures
NameTimeMethod
Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Up to approximately 2 years
Part 2: ORR as Assessed by Initial Investigator ReviewUp to approximately 2 years
Part 1: Number of Participants with Serious Adverse Events (SAEs)Up to approximately 2 years
Part 1: Number of Participants with Reductions in Dosing with BGB-3245Up to approximately 2 years
Part 1: Number of Participants with Adverse Events of Special Interest (AESIs)Up to approximately 2 years
Part 1: Number of Participants with Interruptions to Dosing with BGB-3245Up to approximately 2 years
Part 1: MTD of BGB-3245Up to approximately 2 years
Part 1: RP2D of BGB-3245Up to approximately 2 years
Secondary Outcome Measures
NameTimeMethod
Part 1 and 2: Disease Control Rate (DCR)Up to approximately 2 years
Part 1 and 2: Duration of Response (DoR)Up to approximately 2 years
Part 2: Number of Participants with SAEsUp to approximately 2 years
Part 2: Number of Participants with TEAEsUp to approximately 2 years
Part 2: ORR as Assessed by Central ReviewUp to approximately 2 years
Part 1 and 2: Plasma Concentrations of BGB-3245 and Any Relevant MetabolitesDay 1 of each 28 day cycle (up to approximately 2 years)
Part 1: ORR as Assessed by Investigator Review using RECIST v1.1Up to approximately 2 years
Part 1 and 2: Progression Free Survival (PFS)Up to approximately 2 years
Part 2: Number of Participants with AESIsUp to approximately 2 years
Part 2: Number of Participants with Interruptions to Dosing with BGB-3245Up to approximately 2 years
Part 2: Number of Participants with Reductions in Dosing with BGB-3245Up to approximately 2 years

Trial Locations

Locations (5)

Duke Cancer Institute

🇺🇸

Durham, North Carolina, United States

USOR - Virginia Cancer Specialists - Fairfax Office

🇺🇸

Fairfax, Virginia, United States

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

City of Hope Comprehensive Cancer Center - Duarte

🇺🇸

Duarte, California, United States

Peter MacCallum Cancer Centre

🇦🇺

Melbourne, Victoria, Australia

© Copyright 2024. All Rights Reserved by MedPath